Press Releases


Information for the media and for our investors

Formycon Releases Updates on Development Programs and Milestones

For FYB201, new data from the recently completed COLUMBUS-AMD phase III trial in patients with neovascular age-related macular degeneration (nAMD) are available.


Formycon Reports Nine-Month Figures for 2018

The turnover of the Formycon group increased significantly compared with the first nine months of 2017.


Formycon Reports Financial and Operating Results for the First Half Year of 2018

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars


Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars


Formycon with Significant Growth in Turnover and Earnings in the First Quarter of 2018

Formycon has significantly improved its revenue and earnings in the first quarter of 2018 compared to the same period of the previous year.


Formycon With Successful 2017 Financial Year

Formycon has ended the 2017 financial year successfully and has once again significantly advanced the development of its product candidates.


Biosimilar Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study

According to an interim result, the primary endpoint has been achieved in the COLUMBUS-AMD phase III trial, which is intended to demonstrate the efficacy, safety and immunogenicity of FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).


Formycon and Bioeq Achieve Important Milestone: Biosimilar Ranibizumab Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study

In the COLUMBUS-AMD Trial the primary endpoint has been achieved, thus confirming comparable efficacy between FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).


Formycon Ranks 7th in the Financial Times List of Europe’s 1000 Strongest-Growing Companies

Formycon has ranked 7th in the FT1000 list compiled by the highly respected business newspaper the Financial Times and data provider Statista, making it the only biotech company to appear in the top ten.


Formycon and Aristo Pharma are Founding a Joint Venture for the Development of FYB202

Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon's biosimilar candidate for Stelara® (ustekinumab).


Formycon Reports Operating and Financial Results for the Third Quarter of 2017

Formycon has again progressed well with the further development of its four biosimilars and confirmed the Euro 25 million sales target for whole of 2017.


Formycon Sets Course for the Future and Confirms Management Board Members until mid-2022

The Supervisory Board of Formycon has extended the appointments of Dr. Carsten Brockmeyer, board member and CEO, and Dr. Nicolas Combé, board member and CFO, until June 30, 2022.


Formycon Reports Financial and Operating Results for the First Half Year of 2017

Formycon has accomplished a successful first half year in 2017. Phase III clinical trial of FYB201 is continuing to progress as planned, the implementation of development cooperation agreement for FYB202 is anticipated for second half of the year


Formycon signs term sheet for development of FYB202 and executes capital increase

Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.


Formycon Publishes Figures for the First Quarter of 2017

The commercial performance of Formycon has again advanced as planned in the first quarter of 2017 and the development of its four biosimilar projects has progressed as expected.